


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Cancel Claims 54-56.

**Listing of Claims:**

1. (original) A compound of structural formula I:



or a pharmaceutically acceptable salt thereof; wherein  
each n is independently 0, 1, or 2;

X, Y and Z are independently selected from the group consisting of:

- (1) CR<sup>1</sup>,
- (2) NR<sup>2</sup>,
- (3) N,
- (4) O, and
- (5) S;

with the provisos that at least one of X, Y and Z is not CR<sup>1</sup> and two of X, Y, and Z cannot be O and/or S;

Ar is phenyl substituted with one to five R<sup>3</sup> substituents;

each R<sup>1</sup> is independently selected from the group consisting of  
hydrogen,

halogen,

hydroxy,

cyano,

C<sub>1-10</sub> alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents

independently selected from halogen or hydroxy,

C<sub>1-10</sub> alkoxy, wherein alkoxy is unsubstituted or substituted with one to five substituents

independently selected from halogen or hydroxy,

C<sub>1-10</sub> alkylthio, wherein alkylthio is unsubstituted or substituted with one to five substituents

independently selected from halogen or hydroxy,

C<sub>2-10</sub> alkenyl, wherein alkenyl is unsubstituted or substituted with one to five substituents

independently selected from halogen, hydroxy, COOH, and COOC<sub>1-6</sub> alkyl,

(CH<sub>2</sub>)<sub>n</sub>COOH,

(CH<sub>2</sub>)<sub>n</sub>COOC<sub>1-6</sub> alkyl,

(CH<sub>2</sub>)<sub>n</sub>CONR<sup>4</sup>R<sup>5</sup>, wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from the group consisting of

hydrogen, tetrazolyl, thiazolyl, (CH<sub>2</sub>)<sub>n</sub>-phenyl, (CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, and C<sub>1-6</sub> alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy

are unsubstituted or substituted with one to five halogens;

or R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a

heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and

morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy,

wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

(CH<sub>2</sub>)<sub>n</sub>-NR<sup>4</sup>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-OCONR<sup>4</sup>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>R<sup>6</sup>,

(CH<sub>2</sub>)<sub>n</sub>-NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>,

(CH<sub>2</sub>)<sub>n</sub>-NR<sup>7</sup>CONR<sup>4</sup>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-NR<sup>7</sup>COR<sup>7</sup>,

$(\text{CH}_2)_n\text{-NR}^7\text{CO}_2\text{R}^6$ ,

$(\text{CH}_2)_n\text{-COR}^7$ ,

$(\text{CH}_2)_n\text{-C}_{3-6}$  cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy,  $\text{C}_{1-6}$  alkyl, and  $\text{C}_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(\text{CH}_2)_n\text{-aryl}$ , wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, cyano, hydroxy,  $\text{NR}^7\text{SO}_2\text{R}^6$ ,  $\text{SO}_2\text{R}^6$ ,  $\text{CO}_2\text{H}$ ,  $\text{COOC}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkyl, and

$\text{C}_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(\text{CH}_2)_n\text{-heteroaryl}$ , wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen,  $\text{C}_{1-6}$  alkyl, and  $\text{C}_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

$(\text{CH}_2)_n\text{-heterocyclyl}$ , wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen,  $\text{C}_{1-6}$  alkyl, and  $\text{C}_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene ( $\text{CH}_2$ ) carbon atom in  $\text{R}^1$  is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and  $\text{C}_{1-4}$  alkyl unsubstituted or substituted with one to five halogens;

each  $\text{R}^2$  is independently selected from the group consisting of

hydrogen,

$\text{C}_{1-10}$  alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

$\text{C}_{2-10}$  alkenyl, wherein alkenyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,

$(\text{CH}_2)_n\text{COOH}$ ,

$(\text{CH}_2)_n\text{COOC}_{1-6}$  alkyl,

$(\text{CH}_2)_n\text{CONR}^4\text{R}^5$ , wherein  $\text{R}^4$  and  $\text{R}^5$  are independently selected from the group consisting of hydrogen, tetrazolyl, thiazolyl,  $(\text{CH}_2)_n\text{-phenyl}$ ,  $(\text{CH}_2)_n\text{-C}_{3-6}$  cycloalkyl, and  $\text{C}_{1-6}$  alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

or R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, (CH<sub>2</sub>)<sub>n</sub>COOC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens or one phenyl;

(CH<sub>2</sub>)<sub>n</sub>-COR<sup>7</sup>,

(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>R<sup>6</sup>,

(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, cyano, hydroxy, NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, CO<sub>2</sub>H, C<sub>1-6</sub> alkyloxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

(CH<sub>2</sub>)<sub>n</sub>-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>2</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens;

each  $R^3$  is independently selected from the group consisting of

hydrogen,  
halogen,  
cyano,  
hydroxy,  
 $C_{1-6}$  alkyl, unsubstituted or substituted with one to five halogens, and  
 $C_{1-6}$  alkoxy, unsubstituted or substituted with one to five halogens;

$R^6$  is independently selected from the group consisting of tetrazolyl, thiazolyl,  $(CH_2)_n$ -phenyl,  $(CH_2)_n$ - $C_{3-6}$  cycloalkyl, and  $C_{1-6}$  alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy,  $C_{1-6}$  alkyl, and  $C_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene ( $CH_2$ ) carbon atom in  $R^6$  is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy,  $C_{1-4}$  alkyl, and  $C_{1-4}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

each  $R^7$  is hydrogen or  $R^6$ ;

$R^8$ ,  $R^9$  and  $R^{10}$  are each independently selected from the group consisting of

hydrogen,  
cyano,  
 $(CH_2)_nCOOH$ ,  
 $(CH_2)_nCOOC_{1-6}$  alkyl,  
 $C_{1-6}$  alkyloxycarbonyl,  
 $C_{1-10}$  alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy,  $C_{1-6}$  alkoxy, and phenyl- $C_{1-3}$  alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,  
 $(CH_2)_n$ -aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy,  $C_{1-6}$  alkyl, and  $C_{1-6}$  alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,


(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

(CH<sub>2</sub>)<sub>n</sub>CONR<sup>4</sup>R<sup>5</sup>, wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from the group consisting of hydrogen, tetrazolyl, thiazolyl, (CH<sub>2</sub>)<sub>n</sub>-phenyl, (CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, and C<sub>1-6</sub> alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;


or R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, (CH<sub>2</sub>)<sub>n</sub>COOC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens or one phenyl; and

wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>8</sup>, R<sup>9</sup> or R<sup>10</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens.


2. (original) The compound of Claim 1 of the structural formula Ia wherein the carbon atom marked with an \* has the *R* stereochemical configuration



3. (original) The compound of Claim 1 of the structural formula Ib




4. (original) The compound of Claim 3 of the structural formula Ic wherein the carbon atom marked with an \* has the *R* stereochemical configuration




5. (original) The compound of Claim 3 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

6. (original) The compound of Claim 1 of the structural formula le




7. (original) The compound of Claim 6 of the structural formula If wherein the carbon atom marked with an \* has the *R* stereochemical configuration




8. (original) The compound of Claim 6 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

9. (original) The compound of Claim 1 of the structural formula Ih




10. (original) The compound of Claim 9 of the structural formula Ii wherein the carbon atom marked with an \* has the *R* stereochemical configuration




11. (original) The compound of Claim 9 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

12. (original) The compound of Claim 1 of the structural formula Ik






13. (original) The compound of Claim 12 of the structural formula II wherein the carbon atom marked with an \* has the *R* stereochemical configuration




14. (original) The compound of Claim 12 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

15. (original) The compound of Claim 1 of the structural formula In




16. (original) The compound of Claim 15 of the structural formula Io wherein the carbon atom marked with an \* has the *R* stereochemical configuration




17. (original) The compound of Claim 15 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

18. (original) The compound of Claim 1 of structural formula Iq




19. (original) The compound of Claim 18 of the structural formula Ir wherein the carbon atom marked with an \* has the *R* stereochemical configuration




20. (original) The compound of Claim 18 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

21. (original) The compound of Claim 1 of the structural formula It




22. (original) The compound of Claim 21 of the structural formula Iu wherein the carbon atom marked with an \* has the *R* stereochemical configuration




23. (original) The compound of Claim 21 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

24. (original) The compound of Claim 1 of the structural formula Iw




25. (original) The compound of Claim 24 of the structural formula Ix wherein the carbon atom marked with an \* has the *R* stereochemical configuration




26. (original) The compound of Claim 24 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

27. (original) The compound of Claim 1 of the structural formula Iz




28. (original) The compound of Claim 27 of the structural formula Iaa wherein the carbon atom marked with an \* has the *R* stereochemical configuration




29. (original) The compound of Claim 27 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

30. (original) The compound of Claim 1 of the structural formula Iac




31. (original) The compound of Claim 30 of the structural formula Iad wherein the carbon atom marked with an \* has the *R* stereochemical configuration




32. (original) The compound of Claim 30 wherein  $R^9$  and  $R^{10}$  are hydrogen.

33. (original) The compound of Claim 1 of the structural formula Iaf




34. (original) The compound of Claim 33 of the structural formula Ig wherein the carbon atom marked with an \* has the *R* stereochemical configuration




35. (original) The compound of Claim 33 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

36. (original) The compound of Claim 1 of the structural formula Iai




37. (original) The compound of Claim 36 of the structural formula Iaj wherein the carbon atom marked with an \* has the *R* stereochemical configuration




38. (original) The compound of Claim 36 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.

39. (original) The compound of Claim 1 of the structural formula Ial



40. (original) The compound of Claim 39 of the structural formula Ia wherein the carbon atom marked with an \* has the *R* stereochemical configuration



41. (original) The compound of Claim 39 wherein  $R^9$  and  $R^{10}$  are hydrogen.

42. (original) The compound of Claim 1 wherein  $R^3$  is selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl, and methyl.

43. (original) The compound of Claim 1 wherein  $R^1$  is selected from the group consisting of:

hydrogen,

halogen,

hydroxy,

$C_{1-10}$  alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents

independently selected from halogen or hydroxy,

$C_{2-10}$  alkenyl, wherein alkenyl is unsubstituted or substituted with one to five substituents

independently selected from halogen, hydroxy, COOH, and COOC<sub>1-6</sub> alkyl,

$(CH_2)_n$ - $C_{3-6}$  cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three

substituents independently selected from halogen, hydroxy,  $C_{1-6}$  alkyl, and  $C_{1-6}$  alkoxy,

wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and

(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, cyano, hydroxy, NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, CO<sub>2</sub>H, COOC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>1</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens;

44. (original) The compound of Claim 43 wherein R<sup>1</sup> is selected from the group consisting of  
hydrogen,  
methyl,  
ethyl,  
trifluoromethyl,  
CH<sub>2</sub>CF<sub>3</sub>,  
CF<sub>2</sub>CF<sub>3</sub>,  
phenyl,  
4-(methoxycarbonyl)phenyl,  
4-fluorophenyl,  
4-(trifluoromethyl)phenyl,  
4-(methylsulfonyl)phenyl,  
cyclopropyl,  
fluoro,  
chloro,  
bromo, and  
2-(methoxycarbonyl)vinyl.

45. (original) The compound of Claim 1 wherein R<sup>2</sup> is selected from the group consisting of  
hydrogen,



C<sub>1-6</sub> alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,  
(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, CN, hydroxy, NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, CO<sub>2</sub>H, COOC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, and  
C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and  
wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>2</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens.

46. (original) The compound of Claim 45 wherein R<sup>2</sup> is selected from the group consisting of:

hydrogen,  
methyl,  
CH<sub>2</sub>CF<sub>3</sub>,  
isobutyl,  
4-(trifluoromethyl)benzyl, and  
4-fluorobenzyl.

47. (original) The compound of Claim 1 wherein R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are independently selected from the group consisting of:

hydrogen,  
C<sub>1-10</sub> alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkoxy,  
and phenyl-C<sub>1-3</sub> alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,  
(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,


(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>8</sup>, R<sup>9</sup> or R<sup>10</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens.

48. (original) The compound of Claim 47 wherein R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are each independently selected from the group consisting of

hydrogen,  
trifluoromethyl,  
methyl,  
ethyl,  
cyclopropyl,  
CH<sub>2</sub>-Ph, and  
CH<sub>2</sub>(4-F-Ph).

49. (original) The compound of Claim 48 wherein R<sup>9</sup> and R<sup>10</sup> are hydrogen.





50. (original) The compound of Claim 49 which is selected from the group consisting of:




Serial No.: 10/542,214

Case No.: 21317YP

Page No.: 20





or a pharmaceutically acceptable salt thereof.

51. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

52. (previously cancelled)

53. (previously presented) A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

54-56. (cancelled)